Cardiovascular revascularization medicine : including molecular interventions
-
Cardiovasc Revasc Med · Feb 2021
Meta AnalysisSafety and Efficacy of Colchicine in Patients With Coronary Artery Disease: A Systematic Review and Meta-Analysis.
Given current evidence, the use of colchicine for the prevention of adverse cardiovascular events in patients with coronary artery disease (CAD) remains controversial. ⋯ In patients with CAD presenting with an acute coronary syndrome or stable angina, colchicine might offer no significant reduction in MACE and could potentially be harmful due to a significantly higher risk of GI-related adverse events.
-
Cardiovasc Revasc Med · Sep 2020
ReviewCost-effectiveness of transcatheter aortic valve intervention (TAVI) compared to surgical aortic valve replacement (SAVR) in low-intermediate surgical risk patients.
Transcatheter aortic valve intervention (TAVI) is known to be non-inferior to surgical aortic valve replacement (SAVR) in low-intermediate surgical risk patients. This present systematic review was conducted to analyse the cost-effectiveness of TAVI in this patient population. ⋯ TAVI is likely to be a cost-effective alternative to SAVR in low-intermediate risk patients. More studies on low risk patients is needed.
-
Cardiovasc Revasc Med · Sep 2020
ReviewCost-effectiveness of transcatheter aortic valve intervention (TAVI) compared to surgical aortic valve replacement (SAVR) in low-intermediate surgical risk patients.
Transcatheter aortic valve intervention (TAVI) is known to be non-inferior to surgical aortic valve replacement (SAVR) in low-intermediate surgical risk patients. This present systematic review was conducted to analyse the cost-effectiveness of TAVI in this patient population. ⋯ TAVI is likely to be a cost-effective alternative to SAVR in low-intermediate risk patients. More studies on low risk patients is needed.
-
Cardiovasc Revasc Med · Sep 2020
ReviewImplementation of Institutional Discharge Protocols and Transition of Care Following Acute Coronary Syndrome.
Despite improvements in acute care and survival following acute coronary syndrome (ACS) hospitalization, readmission remains common. In response, individual institutions have begun to develop their own protocols to reduce variability of care and readmission rates. ⋯ TABLE OF CONTENTS This review discusses approaches for developing and implementing institutional discharge protocols for continuity of care for patients with acute coronary syndrome. The discussion revolves around key components and objectives of a discharge protocol for facilitating successful transition of care.
-
Cardiovasc Revasc Med · Aug 2020
ReviewGuidelines for Balancing Priorities in Structural Heart Disease During the COVID-19 Pandemic.
During the novel coronavirus disease 2019 (COVID-19) pandemic, many hospitals have been asked to postpone elective and surgical cases. This begs the question, "What is elective in structural heart disease intervention?" The recently proposed Society for Cardiovascular Angiography and Interventions/American College of Cardiology consensus statement is, unfortunately, non-specific and insufficient in its scope and scale of response to the COVID-19 pandemic. We propose guidelines that are practical, multidisciplinary, implementable, and urgent. ⋯ During the surge phase, treatment should broadly be limited to those at increased risk of complications in the near term. During the peak phase, treatment should be limited to inpatients for whom it may facilitate discharge. Keeping our patients and ourselves safe is paramount, as well as justly rationing resources.